Tolerability and Bioavailability of the P144 Peptide Inhibitor of TGF-β1 After Topical Administration in Healthy Volunteers

NCT ID: NCT00656825

Last Updated: 2008-11-05

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 36 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-03-31
• Study Completion Date: 2007-06-30

Brief Summary

Transforming growth factor-beta 1 (TGF-β1) is consistently over expressed in most fibrotic diseases and displays a variety of profibrotic effects in fibroblasts. Activation of TGF-β receptors induces the activation of several kinase signalling cascades leading to the phosphorylation of SMAD proteins as well as to the activation of SMAD-independent kinases that collectively activate ECM synthesis and fibroblast growth and differentiation into myofibroblasts. TGF-β1 is one of the main mediators in the fibrotic process, associated to both scarring and a long list of pathologies related to chronic inflammation and which affect all type of organs and tissues. An increase in TGF-β1 mRNA and protein levels has been described in these processes. Peptide 144 (P144) is the acetic salt of a 14mer peptide from human TGF-β1 type III receptor (betaglycan). P144 TGF-β1-inhibitor has been specifically designed to block the interaction between TGF-β1 and TGF-β1 type III receptor, thus blocking its biological effects. P144 has shown significant antifibrotic activity in mice receiving repeated subcutaneous injections of bleomycin, a widely accepted animal model of human scleroderma, and could contribute to the development. The purpose of this study is to assess the tolerability and safety of topical application of P144 in healthy volunteers.

Detailed Description

Three different formulations of DIGNA P144 cream (containing 100 μg/mL, 200 μg/mL and 300 μg/mL) will be tested in healthy volunteers. Tolerability evaluation is performed through the specific cutaneous tolerability visual scale of Frosch and Kligman. Safety assessment is carried out by studying vital signs, physical examination, by performing laboratory tests, electrocardiogram and reporting any adverse events experienced. This is the first time that P144 will be administered in humans. The topical route has been chosen since the indication for which P144 is going to be clinically developed will be cutaneous sclerosis associated to scleroderma.

Systemic sclerosis or scleroderma is a multisystemic disorder characterized by the excessive synthesis and deposition of extracellular matrix proteins that result in the fibrosis of skin and visceral organs (including gastrointestinal tract, lungs, heart and kidneys).

The pathogenesis of scleroderma is complex and still poorly understood, but major pathways involved in the development of the condition are microvascular and immunological abnormalities, as well as dysregulation of fibroblast activity. One of the key molecules involved in the pathogenesis of skin fibrosis is the TGF-β1; TGF-β1 is a cytokine directly responsible for fibroblasts proliferation and collagen and extracellular matrix overproduction.

The affected skin of patients with systemic sclerosis gradually becomes firm, thickened and eventually tightly bound to underlying subcutaneous tissue (indurative phase). It loses hair, oil, and sweat glands becoming dry and coarse. Changes begin distally in the extremities and advance proximally. Lesions develop over a period of time varying from months to a few years. In patients with limited scleroderma, only the skin of fingers, hands, face and lower arms and legs is affected. On the contrary, patients with the diffuse cutaneous disease, skin changes will become generalized, involving initially the extremities and followed by the face and trunk. Rapid progression of these changes over a 2 to 3 year period is usually associated with a greater risk of visceral disease. After several years of disease, the skin may soften and return to normal thickness or become thin and atrophic.

There is currently no approved specific treatment for skin fibrosis in systemic sclerosis neither in the European Union nor the United States of America. P144 belongs to a peptide family that is able to inhibit TGF-β1 in both in vitro and in vivo models characterized by excessive TGF-β1 function. Topical application of P144 exerts a preventive effect precluding the induction of skin fibrosis and the accumulation of collagen in these animals and also has shown its therapeutic properties reducing the skin fibrosis and soluble collagen content in mice with established fibrosis.

Conditions

Healthy

Keywords

P144; TGF-β1; Healthy volunteers; Cutaneous tolerability; Skin fibrosis; systemic scleroderma; systemic sclerosis; Safety

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Blinding Strategy: DOUBLE

Study Groups

Panel I

The first 12 subjects will be selected and ranodmized in order to receive the first treatment dose of 100 μg/mL or placebo in a 8:4 ratio

Group Type: ACTIVE_COMPARATOR

P144 cream

Intervention Type: DRUG

P144 cream will be given at a dose of 100 μg/mL

Panel II

The second 12 subjects will be selected and randomized in order to receive the second treatment dose of 200 μg/mL or placebo in a 8:4 ratio

Group Type: ACTIVE_COMPARATOR

P144 cream

Intervention Type: DRUG

P144 cream will be given at a dose of 200 μg/mL

Panel III

The third 12 subjects will be selected and randomized in order to receive the third treatment dose of 300 μg/mL or placebo in a 8:4 ratio

Group Type: ACTIVE_COMPARATOR

P144 cream

Intervention Type: DRUG

P144 cream will be given at a dose of 300 μg/mL

Placebo

Patients from each panel will be given placebo in a 4:8 ratio.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo will be randomly given to 4 subjects in each panel

Interventions

P144 cream

P144 cream will be given at a dose of 100 μg/mL

Intervention Type: DRUG

P144 cream

P144 cream will be given at a dose of 200 μg/mL

Intervention Type: DRUG

P144 cream

P144 cream will be given at a dose of 300 μg/mL

Intervention Type: DRUG

Placebo

Placebo will be randomly given to 4 subjects in each panel

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Capable of understanding and willing to provide signed and dated written voluntary informed consent before any protocol specific procedures are performed.
• Age between 18 and 45 years old
• Skin phenotype I to IV following Fitzpatrick's classification scale
• BMI between 20-29 kg/sqm
• Not clinically relevant alterations in: arterial pressure, cardiac frequency, analytical values (Hematology, Biochemistry, Urianalysis, Coagulation, Serology, Toxics)

Exclusion Criteria

• Pregnany or lactancy
• Allergy to any medication
• Subjects with skin illnesses or systemic illnesses with skin afectation
• History of drug abuse or regular consumption of alcohol
• Participation in other clinical trials 3 months before the signature of the informed consent
• UV exposure or sun exposure on the zone to be treated
• History of skin hypersensitivity
• Chronic treatment with anti-inflammatories or anti-histaminics
• Treatment with corticoids on the previous month
• Hyperpigmentation on the zone to be treated

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Digna Biotech S.L.

INDUSTRY

Sponsor Role: collaborator

ISDIN

INDUSTRY

Sponsor Role: lead

Responsible Party

ISDIN

Principal Investigators

Belén Ruiz, MD

Role: PRINCIPAL_INVESTIGATOR

Hospital Universitario Puerta de Hierro

Belén Sádaba, MD

Role: PRINCIPAL_INVESTIGATOR

Clínica Universitaria de Navarra

Locations

Hospital Universitario Puerta de Hierro

Madrid, Madrid, Spain

Clínica Universitaria de Navarra

Pamplona, Pamplona, Spain

Countries

Spain

Other Identifiers

2006-002755-33

Identifier Type: -

Identifier Source: secondary_id

NAFB001-SS-01

Identifier Type: -

Identifier Source: org_study_id